|
|
Summer has officially begun, with schools finishing last week but not before one final closure for the extreme heat. British Columbia is now officially out of its longest-ever state of emergency and into Step 3 of the four-step recovery plan. The province has reached around 80% coverage in adult vaccination and the daily bulletins by Dr. Henry and Minister Dix are discontinued.
Already dots are being connected between health care, pandemic preparedness and the life sciences sector.
“As we have learned, pandemics do not care if we are ready for them or not. Let's take the steps that we need to take now to rebuild our basic science capabilities. The health of future Canadians may well depend on what we invest in today,” write Abraham Fuks and Senator Stan Kutcher in a recent op-ed for The Hill Times.
|
|
This was also echoed during Resilient Health’s virtual roundtable, which focused on the Life Sciences Can campaign and its recent call for a National Life Sciences Strategy for Canada. Life Sciences BC CEO and President, Wendy Hurlburt joined panelists to discuss How a Robust Canadian Life Sciences Strategy Will Drive Health and Wealth. You can catch up with the podcast here
Members in the News
Our collective future includes learning from the last 16 months. LSBC member and Gold Sponsor, AbCellera continues to receive coverage, with an article describing the $190M manufacturing facility planned in Vancouver as ‘preparation for future pandemics’
Next week, Dr. Pieter Cullis, an LSBC Board member, takes part in a UBC Faculty of Medicine discussion on the obstacles academic research faces in translating discoveries into healthcare deliverables.
LSBC News
Our Events team at LSBC has wrapped up a successful season. They delivered 24 events to a total of 3,315 attendees over the last year. Our top events -- the 2nd Annual Career Connect Day presented by BioTalent Canada, the 6th Annual Access to Innovation, and the 2020 Investor Summit, presented by Lumira Ventures – each gathered more than 350 attendees.
Tim Hennessy, LSBC Manager, Events, notes that despite going virtual, our audience continues to grow, bringing eyes onto BC life sciences from around the world. In addition to registrations from Canada and the US, we've seen attendees from many other countries including India, United Arab Emirates, Nigeria, China, Poland and South Africa. This may explain why we're also seeing an increase in visitors to the LSBC website from around the world - make sure your member profile is up-to-date for our new visitors and apply for our Investor Readiness Program so you’re well prepared!
|
|
Advertising Opportunity
Our annual magazine, Life Sciences 2021, in production with Business in Vancouver, hits the stands in late September to coincide with our annual Awards ceremony. Advertising is available. The deadline for an ad buy is August 11; further details and a media kit are available.
Please contact Laura Torrance, Sales Manager with BIV on 604-608-5145 or ltorrance@biv.com
Getting vaccinated can bring us all back together, faster. Getting back to doing all of the things we used to love, and visiting all of the places we used to go. Fastertogether.ca #FasterTogether
LSBC Team
|
|
|
|
Investor Readiness Program – Open for Applications |
Are you a B.C SME in the life sciences industry? Looking to learn and get experience in pitching for potential investors? Become investor-ready with LSBC’s Investor Readiness Program!
A 7-month program designed around individual coaching and complemented by educational workshops, goal setting, peer-to-peer feedback, and conference opportunities, this program brings together SMEs & matches them with experienced and well-networked life sciences EIRs. Apply here
For questions regarding the program, please contact William Burrows, Director of Business &Operations
|
|
|
|
SaNOtize Research and Development Corporation (“SaNOtize” or “the Company”) today announced that Enovid, SaNOtize’s Nitric Oxide Nasal Spray (NONS) that protects from viruses and was shown to reduce SARS-CoV-2 viral load in a Phase II trial, is now available in pharmacies throughout Israel. READ MORE
|
|
|
|
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 4:00 p.m. ET. The presentation will be webcast live and available for replay on Zymeworks’ website here. READ MORE
|
|
|
|
entrepreneurship@UBC’s CORE program supports UBC entrepreneurs (faculty, staff, students, recent UBC alumni) who are driving innovation through disruptive technologies, ideas and trends. CORE works with entrepreneurs who are building solutions founded in tech and innovation, helping to develop their startup through practical business training and dee mentorship to launch ideas into thriving companies capable of shifting industries. READ MORE
|
|
|
|
AbCellera will build a manufacturing facility in Vancouver, Canada to prepare for future pandemics and advance their own clinical pipeline.
The 130,000 square-foot Vancouver facility will produce therapeutic antibodies making it the first of its kind in Canada. READ MORE
|
|
|
|
Incisive Genetics Inc. (“IG”), a privately-held biotech company specializing in non-viral delivery methods for targeted gene therapies, today announced the formation of its Scientific Advisory Board (SAB) and the appointment of Dr. Michael R. Hayden as chairperson. READ MORE
|
|
|
|
InMed Pharmaceuticals Inc., a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has entered into a non-binding letter of intent (the “LOI”) to acquire BayMedica Inc. (“BayMedica”), a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids. READ MORE
|
|
|
|
UBC’s School of Biomedical Engineering (SBME) invites LSBC members to propose a project for our Capstone Design Course, to be undertaken by 4th-year undergraduate student teams from Sept 2021-May 2022, by filling out this submission form by August 1st. Participating organizations have benefitted by promoting their organization to UBC students and researchers, working with potential future employees, as well as receiving custom solutions and prototypes for evaluation. READ MORE
|
|
|
|
entrepreneurship@UBC’s Lab2Launch Venture Building program is for UBC researchers and scientists who are focusing on the development of a scientific or technological innovation which is unique and proprietary, propelling them through venture creation, team building, investment and growth. Apply here
|
|
|
|
Bold Therapeutics, a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug Application (IND) amendment for BOLD-100-001, allowing for the addition of clinical trial sites in the United States, starting with H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida and the University of California, Los Angeles in Los Angeles, California. READ MORE
|
|
|
|
Akili’s newly launched treatment for ADHD is a prescription—but not a drug. It's a video game. And the company is taking a fittingly digital approach to launching the first-of-its-kind FDA-approved product.
|
|
|
|
SFU VentureLabs supports many startups in the Health and Life Sciences space. We are seeing a need for specialized programming and services to meet their needs. To address this need, SFU VentureLabs is seeking to understand what services are available today, and where there are gaps, to help us refine and develop new programming and services that will provide high value support for existing and future Health and Life Sciences early stage and growing new ventures.
Deadline July 10th, 2021
|
|
 |
Satisfai Health is a leading medical solutions provider specializing in AI applications applied to large addressable markets in gastroenterology. Its solutions deliver real-time analysis of medical imagery and provide clinicians with real-time decision-making intelligence that dramatically improve patient outcomes. Satisfai is currently working on the “ai4gi” commercial joint venture with Olympus America Inc and Imagia to develop and commercialize an AI solution for real-time clinical decision support during screening and surveillance colonoscopy procedures.
|
|
|
|
Since 1990, Aurora has been serving the global scientific research community through the development of innovative laboratory solutions. Headquartered in Vancouver, Canada, the company started manufacturing analytical instrumentation based on a patented capacitively coupled plasma emission technology. In 2000, Aurora became the first to develop a non-radioactive, label-free technology for the study and high throughput screening of ion channel and transporter targets.
|
|
|
|
|
|
PERSPECTIVES ON GLOBAL HEALTHCARE INNOVATION |
What’s driving innovation in life science and healthcare? SVB is committed to serving the ecosystem by providing industry-leading reports featuring proprietary analysis and targeted outlooks to help companies and investors achieve their goals. Twice a year we publish deep-dive analyses describing fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Our deep relationships with top life science and healthcare entrepreneurs and investors inform our insights and give us a vantage point unlike any other bank. To find out more about Silicon Valley Bank click here
|
|
|
|
Posting A Job on the LSBC Website |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish After your first five reposts, you will also receive 25% off all job postings on The Petri Dish. Want more info? CONTACT: Peter McLoughlin - talent@lifesciencesbc.ca
|
|
|
|
|
|
|
